Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

355
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
355
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

689
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
689
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

1.1K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.1K
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

925
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
925
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

1.1K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.1K
Restless Leg Syndrome and Night Terrors01:27

Restless Leg Syndrome and Night Terrors

583
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
583

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Properdin deficiency or anti-properdin treatment ameliorates disease in the C3 gain-of-function mouse model of atypical haemolytic uraemic syndrome.

Frontiers in immunology·2026
Same author

C3 Glomerulonephritis Associated With Anti-complement Factor B Antibodies Following Anti-cancer Treatment With Pembrolizumab.

Kidney medicine·2026
Same author

Complement biomarkers during iptacopan treatment - Authors' reply.

Lancet (London, England)·2026
Same author

Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study.

Health technology assessment (Winchester, England)·2026
Same author

Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial.

The Lancet regional health. Europe·2026
Same author

Current and Emerging Therapies for C3 Glomerulopathy and Primary (Idiopathic) Immune Complex Membranoproliferative Glomerulonephritis.

Kidney international reports·2026

Related Experiment Video

Updated: Feb 13, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

22.2K

Atypical hemolytic uremic syndrome.

David Kavanagh1, Timothy H J Goodship

  • 1The Institute of Human Genetics, International Centre for Life, Newcastle University, Newcastle upon Tyne, UK. david.kavanagh@ncl.ac.uk

Current Opinion in Hematology
|July 9, 2010
PubMed
Summary

Atypical hemolytic uremic syndrome (aHUS) involves complement overactivation. New genetic factors, like thrombomodulin mutations, are identified, and complement inhibitors show promise for targeted aHUS therapy.

More Related Videos

EEG Mu Rhythm in Typical and Atypical Development
11:50

EEG Mu Rhythm in Typical and Atypical Development

Published on: April 9, 2014

26.6K
Clinical Examination Protocol to Detect Atypical and Classical Scrapie in Sheep
13:42

Clinical Examination Protocol to Detect Atypical and Classical Scrapie in Sheep

Published on: January 19, 2014

14.1K

Related Experiment Videos

Last Updated: Feb 13, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

22.2K
EEG Mu Rhythm in Typical and Atypical Development
11:50

EEG Mu Rhythm in Typical and Atypical Development

Published on: April 9, 2014

26.6K
Clinical Examination Protocol to Detect Atypical and Classical Scrapie in Sheep
13:42

Clinical Examination Protocol to Detect Atypical and Classical Scrapie in Sheep

Published on: January 19, 2014

14.1K

Area of Science:

  • Nephrology
  • Immunology
  • Genetics

Background:

  • Atypical hemolytic uremic syndrome (aHUS) is distinguished from thrombotic thrombocytopenic purpura by complement system overactivation.
  • Genetic factors and autoantibodies against complement regulatory proteins are implicated in aHUS pathogenesis.
  • Recent findings highlight thrombomodulin mutations as a novel risk factor for aHUS.

Purpose of the Study:

  • To review recent advancements in understanding the molecular basis of aHUS.
  • To discuss the role of genetic factors and complement dysregulation in aHUS.
  • To evaluate the therapeutic potential of complement inhibitors in aHUS.

Main Methods:

  • Review of recent scientific literature on aHUS.
  • Analysis of genetic risk factors and their impact on complement regulation.
  • Evaluation of clinical outcomes for patients treated with complement inhibitors.

Main Results:

  • Identification of thrombomodulin mutations as a new genetic risk factor for aHUS.
  • Recognition that a combination of risk factors may trigger aHUS.
  • Successful use of the complement inhibitor eculizumab in treating aHUS patients.

Conclusions:

  • Molecular characterization of aHUS enables targeted therapeutic strategies.
  • Early results for eculizumab in aHUS treatment are promising, with further clinical trial data anticipated.